Tub 2.1, a monoclonal antibody commonly used to measure cellular tubulin content, is widely believed to recognize all b-tubulin isotypes. Though it has been used for more than two decades, the epitope for this antibody is not well established. We report for the first time that contrary to common belief, this antibody does not react with all isotypes of b-tubulin. Of the seven vertebrate btubulins, the more divergent class V and VI isotypes are not recognized by this antibody. Among the isotypes that do react, binding is similar for b2, b3, b4a and b4b but lower for b1, the most abundant isotype. Expression of chimeric tubulins verified that the epitope for Tub 2.1 is near the C-terminal end of b-tubulin. Site-directed mutagenesis of this region in nonreactive b5 to match the sequence of b4b resulted in strong reaction to Tub 2.1 and narrowed the epitope to amino acids 431-436.
Introduction
Microtubules composed of a-and b-tubulin heterodimers are essential for moving vesicles, maintaining cell shape and separating chromosomes during mitosis. Although vertebrate tubulin sequences are highly conserved, significant differences exist, particularly in the b subunit. The most variable region of b-tubulin is the C-terminal 15 amino acids, and it is the amino acid differences in this region that serve as the basis for classifying b-tubulin into seven distinct isotypes (Lopata and Cleveland, 1987) . Some of these b-tubulin isotypes are ubiquitously expressed, while others are only expressed in specific tissues (Sullivan, 1988; Luduena, 1998) . The reason why vertebrates express seven different b-tubulin genes is not well understood. Recently, we showed that modulating expression of some isotypes causes abnormalities in cell growth and alters sensitivity to drugs that target microtubules (Hari et al., 2003; Bhattacharya and Cabral, 2004; Yang and Cabral, 2007) . Other investigators have reported defects in axoneme and platelet function as a result of altering or eliminating specific tubulin isotypes (Hoyle and Raff, 1990; Schwer et al., 2001) . In addition, inappropriate expression of a brain-specific isoform of b-tubulin has been found in a variety of tumors and its presence appears to correlate with patient prognosis (Katsetos et al., 2003; Seve et al., 2005; Ferrandina et al., 2006) . Thus, knowledge of the cellular content of specific b-tubulin isotypes can be very important in understanding tumor progression and prognosis (Seve and Dumontet, 2008 ).
Due to close sequence homology, most antibodies to a-tubulin react with all isotypes. The initial antibodies generated against b-tubulin also reacted with multiple isotypes (Gozes and Barnstable, 1982; Blose et al., 1984) . It was only later, when detailed sequence information on different b-tubulin isotypes became available, that it became possible to create isotype-specific antibodies (Lewis et al., 1987; Lopata and Cleveland, 1987; Banerjee et al., 1988 Banerjee et al., , 1990 Lee et al., 1990) . These more specific antibodies have been useful for characterizing the tubulin isotype composition of various tissues and cell lines, examining differences in assembly properties of isotypically purified tubulin heterodimers, and exploring changes in tubulin gene expression that occur during disease states or their therapy (Banerjee et al., 1992; Hiser et al., 2006; Ohishi et al., 2007; Cucchiarelli et al., 2008) . Additionally, however, it is frequently necessary to measure changes in total tubulin content resulting from genetic manipulations that may alter tubulin composition (Burkhart et al., 2001; Cabral, 2001) . For these latter studies, it is necessary to employ an antibody that equally recognizes all the different a-or b-tubulin gene products. One of the antibodies that is most frequently used for this purpose is Tub 2.1. This antibody was raised against purified rat brain tubulin and has been thought to recognize all b-tubulin isotypes (Gozes and Barnstable, 1982) . The epitope for Tub 2.1 is still unknown but some reports indicate that it is near the C-terminus of b-tubulin (Matthes et al., 1988) . We now report that this antibody does not react with tubulin isotypes b5 and b6. Among the remaining isotypes, it exhibits reduced reactivity with b1, the major isotype found in most cells. We have narrowed the epitope for Tub 2.1 to residues 431-436 of b-tubulin.
Materials and methods

Construction of plasmids expressing different HAb-tubulin isotypes
Chinese hamster ovary (CHO) b1 (GenBank accession no. U08342); mouse b2 (NP_076205) and b4b (NM_146116); human b3 (BC000748); mouse b4a (NM_009451) and b5 (BC008225); and human b6 (BC033679) cDNAs were all engineered to place a hemagglutinin antigen (HA) tag at the C-terminal end and subcloned into a pTOPneo plasmid as described previously (Gonzalez-Garay et al., 1999) . The plasmids were named pTOPHAb1 through pTOPHAb6. The b1 (Boggs and Cabral, 1987) and b3 (Hari et al., 2003) cDNAs came from our own laboratory, b5 and b6 cDNAs came from American Type Culture Collection (Manassas, VA, USA) and b2, b4a and b4b cDNAs were generous gifts from Nicholas Cowan (New York University).
Construction of hybrid and mutant b-tubulins
pTOPHAb1 and pTOPHAb5 were modified by site-directed mutagenesis to introduce a Bsm1 site between amino acids 417 and 418. Both plasmids were digested with Bsm1 and Not1, and the large fragment from HAb1 was ligated to the small fragment from HAb5 to produce a chimeric tubulin having b1 (1 -417) -b5 (418 -447) sequences followed by the HA-tag. The plasmid was named pTOPHAb1-b5 C . pTOPHAb5 was modified by site-directed mutagenesis to replace amino acids 430 -437 with the cognate residues from HAb4 using the primers 5 0 -CAG TAC CAG GAC GCC ACG GCC GAG GAA GAG GGA GAG TTT GAA GAC GAG GAT GAA GAA G-3 0 and 5 0 -CTT CTT CAT CCT CGT CTT CAA ACT CTC CCT CTT CCT CGG CCG TGG CGT CCT GGT ACT G-3 0 . Mutations were verified by DNA sequencing.
Transfection and isolation of stably transfected cell lines CHO tTA cells expressing the tetracycline (tet) regulated transactivator (Gonzalez-Garay et al., 1999) were seeded into 35-mm tissue culture dishes and transfected with plasmids containing the various HA-tagged b-tubulin isotypes using Lipofectamine (Invitrogen, Carlsbad, CA, USA) as described by the manufacturer. After transfection, cells were incubated overnight in alpha modification of minimum essential medium (aMEM) (Cellgro, Herndon, VA, USA) containing 1 mg/ml tetracycline to repress expression of the ectoptic HAb-tubulins. Cells were then trypsinized and replated in 100-mm dishes containing aMEM, 1 mg/ml tetracycline (Sigma-Aldrich, St Louis, MO, USA) and 2 mg/ml G418 (Cellgro). After 7 -8 days, G418-resistant colonies were isolated and analyzed for expression of HAb-tubulin by western blots.
Electrophoresis and western blots
Transfected cells were grown 24 h without tetracycline to allow expression of HA-tagged b-tubulins and lysed in 1% SDS. Proteins were precipitated with 5 volumes of chilled acetone, resuspended in SDS sample buffer (0.0625 M TrisHCl, pH 6.8, 2.5% SDS, 5% 2-mercaptoethanol, 10% glycerol), fractionated on a 7.5% polyacrylamide SDS minigel and transferred to Protran nitrocellulose membranes (Whatman, Dassel, Germany). The membranes were blocked in PBST (PBS with 0.05% Tween 20) containing 3% dry milk. After washing three times in PBST, the membranes were incubated in a 1:1000 dilution of monoclonal antibody Tub 2.1 (Sigma-Aldrich, St Louis, MO, USA) and 1:15 000 dilution of mouse monoclonal HA antibody (Covance, Princeton, NJ, USA). All membranes were also incubated with a 1:30 000 dilution of actin-specific mouse monoclonal C4 (Chemicon International Inc., Temecula, CA, USA) that acted as a loading control. Incubation was carried out for 1 h at room temperature and membranes were washed again three times with PBST. The membranes were then incubated in 1:2000 dilutions of goat antimouse IgG coupled to Alexa 647 (Invitrogen, Carlsbad, CA, USA) and reacting protein bands were detected by scanning the membranes on a STORM 860 imager (Molecular Dynamics Inc., Sunnyvale, CA, USA). Bands were quantified using ImageJ software (NIH). Fluorescence detection using the Storm imager was used for quantification of bands on western blots because its linear response over several orders of magnitude eliminates many of the problems inherent in the use of film-based detection methods. Band intensities for HAb-tubulins were normalized to actin, and the normalized values from Tub 2.1 divided by anti-HA yielded the relative reactivity for each b-tubulin isotype.
Results
Tub 2.1 reacts with a subset of b-tubulin isotypes
To determine the specificity of Tub 2.1, CHO cells were transfected with cDNAs for each of the seven b-tubulin isotypes. The cDNAs encoded an HA tag at the C-terminal end of the protein to allow the ectopic protein to be separated from endogenous tubulin on SDS polyacrylamide gel electrophoresis (SDS-PAGE), and transcription was controlled by a tetracycline regulated promoter. Following transfection, single clones were isolated, grown in the absence of tetracycline to allow transgene expression and tested for ectopic protein production by immunofluorescence staining using an antibody specific for the HA tag (data not shown). Proteins from cells producing HAb-tubulin were separated by SDS -PAGE, transferred to nitrocellulose and probed with antibody Tub 2.1. We found that HA tagged b1, b2, b3, b4a and b4b as well as the endogenous b-tubulin all reacted with Tub 2.1 and produced two reacting bands at about 50 kDa representing the faster migrating endogenous b-tubulin and the slower migrating ectopic HAb-tubulin (Fig. 1A) . However, cells producing HAb5 and HAb6 exhibited only the endogenous tubulin band, suggesting that the antibody does not recognize the b5 and b6 isotypes. The possibility that the HA tag was interfering with the tubulin-antibody reaction in these two isotypes seemed unlikely as all other isotypes that harbored the same tag produced strong reactions. Also, each transfected cDNA was sequenced to ensure that there were no cloning errors or mutations that might potentially lead to loss of the antibody epitope. As all the ectopic proteins had an HA-tag, the samples were probed with an anti-HA tag antibody to verify that similar levels of ectopic protein were produced in each of the cell lines (Fig. 1B) . The high level of HAb5 and HAb6 detected with this antibody indicated that the failure of Tub 2.1 to recognize these isotypes was not due to low expression.
We next asked whether Tub 2.1 has similar reactivity to each of the isotypes it was able to recognize. To answer this question, the band intensity of each HA-tagged b-tubulin was divided by the intensity of the actin band in the same sample to correct for any differences in gel loading. These normalized values were then compared from blots generated with Tub 2.1 and blots generated with anti-HA, an antibody that should react equally with each of the isotypes. A Tub 2.1/anti-HA ratio was calculated for each isotype and this ratio was set at 1 for HAb1. The ratios for each of the other isotypes relative to HAb1 are summarized in Fig. 1C . The results indicate that Tub 2.1 has similar reactivity to most of the indicated isotypes, but exhibits an almost 2-fold lower reactivity to HAb1, the predominant isotype in most cultured cell lines and tissues (Luduena, 1998).
The C-terminal region of b-tubulin contains the epitope for Tub 2.1
Previous studies indicated that the recognition sequence for Tub 2.1 is located in the C-terminal region of b-tubulin (Matthes et al., 1988) . To confirm this report, we prepared a chimera (HAb1-b5c) in which amino acids distal to residue 417 in b1, an isotype that reacts with Tub 2.1, were replaced with the corresponding sequence from b5, an isotype that is non-reactive. Proteins from cells expressing HAb1 or HAb1-b5 C were then separated by SDS -PAGE and analyzed by western blots. As anticipated, HAb1-b5c was not recognized by Tub 2.1 (Fig. 2) . Thus, sequences downstream from amino acid 417 contain the epitope for this antibody.
Mutations in b5 tubulin restore Tub 2.1 recognition
To further define the epitope recognized by antibody Tub 2.1, we aligned the C-terminal amino acid sequences of mouse tubulin isotypes to identify possible differences that could affect Tub 2.1 binding (Fig. 3) . We found that amino acids 420-430 differed only for b6 and could therefore not be responsible for the inability of the antibody to bind b5. On the other hand, residues beyond amino acid 436 did not share a common motif in isotypes I-IV that could explain why they all reacted with the antibody. All the reactive isotypes had 2 -3 E residues followed by a GEF motif (Fig. 3 , underlined area). These sequence elements were missing in b5 and b6, thereby potentially explaining their lack of reactivity with Tub 2.1. These observations narrowed the epitope to the region between 431 and 436.
To test whether the region between 431 and 436 does, in fact, contain the epitope for Tub 2.1, we altered these residues in b5-tubulin in an attempt to restore recognition by the antibody. The HA-tagged mouse b5 tubulin was modified by site-directed mutagenesis to change its sequence from VNDGEEAF to the corresponding sequence in b4b, AEEEGEF (Fig. 4A) . Proteins from cells transfected with wild-type and mutated HAb5 cDNAs were separated on SDS polyacrylamide gels and blotted with antibodies Tub 2.1 and HA. The results shown in Fig. 4B indicate that only the mutant HAb5 was recognized by Tub 2.1. We conclude that the epitope for Tub 2.1 must be located between amino acids 431 and 436 of b-tubulin.
Discussion
In this study, we tested the ability of monoclonal antibody Tub 2.1 to react with different b-tubulin isotypes. Although isolated in 1980s and widely believed to be a pan-specific b-tubulin antibody, we found that two isotypes, b5 and b6, are not recognized. Moreover, b1-tubulin has an approximately 2-fold lower reactivity than the remaining isotypes. Thus, the use of this antibody to compare cells with potentially different b-tubulin isotype compositions can give erroneous estimates of tubulin content.
For the past several years, we have overexpressed cDNAs for specific b-tubulin isotypes as a way to elucidate their role in microtubule organization, cell growth and drug resistance Hari et al., 2003; Bhattacharya and Cabral, 2004; Yang and Cabral, 2007) . As part of this approach, we estimated how much ectopic protein was produced in transfected cells by measuring the relative intensities of bands representing the transfected HA-tagged tubulin and the endogenous tubulin on western blots using the monoclonal antibody Tub 2.1. This antibody was chosen because it was generally assumed to recognize all b-tubulin isotypes. During our studies, however, we observed that b5 tubulin was not detected even though its presence in our experimental systems could be verified using antibodies that reacted with a C-terminal HA tag attached to the protein (Bhattacharya and Cabral, 2004) and by an antibody specific for the N-terminus of b-tubulin. Experiments using cells transfected with HAb6-tubulin led to a similar result (Yang, Yin and Cabral, unpublished results) . These observations were confirmed and extended by systematically analyzing a panel of protein lysates from cells expressing each of the b-tubulin isotypes (Fig. 1) . All isotypes except b5 and b6 reacted with Tub 2.1. Interestingly, all the reacting isotypes, but not the two nonreacting isotypes b5 and b6, are present in brain (Wang et al., 1986; Lopata and Cleveland, 1987) , a tissue that was used to generate the antibody. Thus, it is not surprising that all forms of b-tubulin present in brain were reported to react with the antibody (Gozes and Barnstable, 1982) . Designating Fig. 2 . The Tub 2.1 epitope is near the C-terminal end of b-tubulin. Cells expressing HAb1 or chimeric HAb1-b5 C were lysed and proteins were fractionated by SDS-PAGE. After transfer to nitrocellulose, the membranes were incubated with Tub 2.1 or HA-tag antibody. An antibody to actin was also included as a gel loading control.
b-Tubulin isotype specificity of Tub 2.1 the antibody as pan-specific was based on existing literature at that time, but was incorrect due to the fact that all the b-tubulin isotypes had not yet been discovered.
The epitope for Tub 2.1 is poorly characterized. Early studies using b-tubulin cleaved with trypsin or chymotrypsin indicated that the epitope is located between amino acids 281 and 446 (Matthes et al., 1988) . Later studies showed that subtilisin cleavage of b-tubulin abolished reactivity with Tub 2.1 (Saoudi et al., 1995) indicating that the epitope is downstream of the subtilisin cut site. On the other hand, a different study proposed that the recognition site is upstream of the enzyme cleavage site (Zambito et al., 2002) . To make things even more complex, the subtilisin cleavage site on b-tubulin varied in different reports. It appears that subtilisin can cleave b-tubulin between residues Glu 433 and Gly 434 (Redeker et al., 1992) or Glu 407 and Phe 408 (Maccioni et al., 1986) . To avoid the problems associated with subtilisin digestion and to better define the epitope for Tub 2.1, we used an approach that involved aligning the sequences of the different tubulin isotypes and identifying a region near the subtilisin cleavage site that could potentially account for the b-tubulin isotype preferences exhibited by the antibody. We found that the amino acid sequence EEEGEF was highly conserved in the isotypes that reacted with Tub 2.1 but was very different in both b5 and b6 tubulins. To test whether this was indeed the epitope, we modified b5 tubulin so that it would have the EEEGEF sequence between residues 431 and 436 and found that it then reacted strongly with the antibody (Fig. 4) . We can therefore state with near certainty that this sequence contains the epitope for antibody Tub 2.1.
An additional important discovery that came from these studies was the observation that Tub 2.1 has reduced reactivity with b1. The fact that the antibody does not recognize two of the b-tubulin isotypes and reacts unequally with the others suggests that some of the conclusions reached in prior studies may have been erroneous. For example, we had concluded from previous studies that overexpression of b3 disrupts microtubule assembly, but only at very high levels of expression (Hari et al., 2003) . However, the estimate of expression was based on the relative intensities of ectoptic HAb3 and endogenous b-tubulin using antibody Tub 2.1. Because we now know that Tub 2.1 has higher reactivity with b3-than with b1-tubulin, an isotype that makes up 70% of the total tubulin in CHO cells (Sawada and Cabral, 1989; Ahmad et al., 1991) , we will have to revise the expression level of HAb3 in those experiments downward.
Other laboratories have also likely misinterpreted data based on the erroneous assumption that Tub 2.1 reacts with all b-tubulin isotypes. Although there is insufficient space to discuss all of these cases, we will use two recent studies as examples of the kinds of problems that can be encountered. Tub 2.1 was used to demonstrate that b-tubulin levels were significantly reduced in transcription factor NF-E2 deficient megakaryocytes (Lecine et al., 2000) . Using an isotypespecific antibody, the authors further showed that b6 was nearly absent in these cells. Because b6 is the predominant isotype in megakaryocytes, the authors assumed that its decrease was responsible for the reduction in total tubulin. Our studies, showing that b6 is not recognized by Tub 2.1, however, suggest that other isotypes must also have been Fig. 3 . Alignment of the C-terminal regions of mouse b-tubulin isotypes. Sequences for all the different mouse b-tubulin isotypes were obtained from NCBI. Identical amino acids are shaded in grey; variant amino acids are in white. The consensus sequence is at the bottom and the putative epitope for Tub 2.1 is underlined. The accession numbers for the sequences used are: b1, NP_035785; b2, NP_076205; b3, NP_075768.1; b4a, NP_033477.2; b4b, NP_666228; b5, NP_080749; b6, NM_001080971. reduced in order to explain the observed decreased reactivity with Tub 2.1. In a follow-up study, platelets from mice that were null for the b6 isotype were reported to have similar levels of total b-tubulin when compared with wild-type mice (Schwer et al., 2001) . Compensatory expression of other b-tubulin isotypes was suggested as a possible mechanism for keeping total tubulin levels constant. Again, however, uncertainty about the ability of their antibody to react with b6 casts doubt as to whether platelet tubulin levels were normal or altered in the null mice.
The recognition that Tub 2.1 has selective and variable reaction with different b-tubulin isotypes will likely limit future use of this antibody. However, the antibody will still be useful for detecting b-tubulin in a wide variety of cell types, for quantifying tubulin in systems for which the isotype composition is known, and for evaluating changes in tubulin levels following treatments that do not alter the tubulin composition. Identification of the epitope for this antibody may also open it up to new uses. The EEEGEF recognition sequence lies in an area that is increasingly being implicated as essential for microtubule function. For example, recent mutational studies have implicated an EGEF(E/D)3 motif in the C-terminal region of tubulin as being important for axoneme structure in Drosophila (Raff et al., 1997; Nielsen et al., 2001 ) and a similar motif has been implicated as essential for cell viability in Tetrahymena (Duan and Gorovsky, 2002) . In the latter case, it was proposed that this region might be involved in binding critical microtubule-associated proteins. Consistent with this idea, another antibody, D66, was reported to inhibit the beat frequency of flagella in sea urchin sperm by potentially inhibiting microtubule/dynein interactions (Audebert et al., 1999) . Given that the epitope for D66 overlaps the epitope for Tub 2.1, the results suggest that Tub 2.1 could be used for similar experiments. It is also possible that Tub 2.1 could be used to probe the state of tubulin posttranslational modifications. Although most posttranslational modifications affect residues outside of the EEEGEF sequence [see (Luduena, 1998) for review], many of them ( polyglycylation of residue 437, polyglutamylation of b2 and b3 at residues 435 and 438, respectively, and phosphorylation of b3 at residue 437) are close enough that Tub 2.1 might affect the binding of enzymes that carry out these modifications, or the modifications might directly interfere with Tub 2.1 binding. Studies to test these predictions should be aided by the identification of the epitope reported here.
